Compare RDNT & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | KRYS |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.3B |
| IPO Year | 1986 | 2017 |
| Metric | RDNT | KRYS |
|---|---|---|
| Price | $74.80 | $244.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $83.60 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 837.5K | 286.6K |
| Earning Date | 11-09-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | N/A | ★ 6.66 |
| Revenue | ★ $1,969,599,000.00 | $373,164,000.00 |
| Revenue This Year | $11.77 | $36.14 |
| Revenue Next Year | $10.76 | $41.80 |
| P/E Ratio | ★ N/A | $36.72 |
| Revenue Growth | 11.09 | ★ 54.51 |
| 52 Week Low | $45.00 | $122.80 |
| 52 Week High | $85.84 | $248.60 |
| Indicator | RDNT | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 81.72 |
| Support Level | $74.96 | $213.83 |
| Resistance Level | $81.35 | $241.65 |
| Average True Range (ATR) | 2.89 | 7.53 |
| MACD | -0.68 | 2.17 |
| Stochastic Oscillator | 2.90 | 89.34 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.